Brian O Mahony/ X
Jul 13, 2026, 19:47
Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Feng Xue on BBM-H901 at ISTH 2026, FIX Gene therapy developed in China.
Approved in China April 2025.
Mean FIX expression after 2 years 61% Distribution :
- 76% FIX more than 40 ,
- 20% FIX less than 40,
- 10% FIX less than 20,
- 5% FIX less than 10,
- 2% FIX less than 2″
Other posts featuring Brian O Mahony on Hemostasis Today
-
Oct 13, 2026, 21:05Francisco Chacón-Lozsán: Heparin-Induced Thrombocytopenia – When an Anticoagulant Triggers Thrombosis
-
Oct 13, 2026, 21:04Aref Zribi: Isolated Tumor Thrombus and the Role of Prophylactic Anticoagulation
-
Oct 13, 2026, 21:01Alex Larson: Why Normal Bloodwork Does Not Always Tell the Whole Story
-
Oct 13, 2026, 20:58Juan Jauregui-Lozano: How Replication Stress Impairs Red Blood Cell Maturation
-
Oct 13, 2026, 20:55Caitlin Raymond: Understanding Platelet Refractoriness Before Ordering More Platelets
-
Oct 13, 2026, 20:54Sanja Seratlic: How Cow Feeding Systems Influence the Anti-Platelet Properties of Cheddar Cheese
-
Oct 13, 2026, 20:50Ruchika Goel: Cord Blood Red Blood Cells as a Physiologically Aligned Transfusion Strategy
-
Oct 13, 2026, 20:47Sophia Delicou: Strengthening Transfusion Safety Through Advanced Screening and Haemovigilance
-
Oct 13, 2026, 20:45Lydia Pecker: Alloimmunization and Transfusion Indications in Sickle Cell Disease Pregnancy